Restless Legs Syndrome Clinical Trial
Official title:
Study RXP110908, a Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance
The purpose of this study is to assess the efficacy and safety of GSK1838262 extended release tablets in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance.
Double-blind, multi-center, placebo-controlled, 2-period crossover study which assessed the efficacy and safety of gabapentin enacarbil (GEn; GSK1838262; XP13512) extended release tablets in adults with Restless Legs Syndrome (RLS)-associated sleep disturbance. One hundred thirty-six (136) adult subjects with RLS-associated sleep disturbance and periodic limb movements (PLM) were randomized from 23 centers in the United States. Subjects who met all eligibility criteria were randomized to receive a treatment sequence of GEn:placebo or placebo:GEn. Investigational product was taken with food at approximately 5pm. Investigational product was dosed as 600mg/day x3 days followed by 1200mg/day x25 days for each 4-week treatment period. There was a 1-week taper at 600mg after each treatment period followed by a 1-week washout between treatments. Polysomnography (PSG) was used to objectively evaluate changes in sleep and PLMs. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05985421 -
Gut Microbiota and Bacterial Translocation in Restless Legs Syndrome
|
||
| Recruiting |
NCT04786314 -
The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome
|
N/A | |
| Completed |
NCT01455012 -
Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
|
Phase 4 | |
| Terminated |
NCT01192503 -
Safety and Efficacy of Rasagiline in Restless Legs Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT00721279 -
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
|
N/A | |
| Completed |
NCT00530530 -
ASP8825 - Study in Patients With Restless Legs Syndrome
|
Phase 2 | |
| Completed |
NCT00375284 -
A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
|
Phase 4 | |
| Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
| Completed |
NCT00479531 -
Sequential Compression Devices for Treatment of Restless Legs Syndrome
|
Phase 3 | |
| Recruiting |
NCT05581576 -
Pitolisant in Refractory Restless Legs Syndrome
|
Phase 4 | |
| Active, not recruiting |
NCT03218969 -
Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04144790 -
Impact of Iron Supplementation Treatment on Brain Iron Concentrations
|
||
| Completed |
NCT05787080 -
Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS)
|
N/A | |
| Not yet recruiting |
NCT05529095 -
Sublingual Apomorphine in Refractory Restless Legs Syndrome
|
Phase 4 | |
| Recruiting |
NCT05044520 -
Clinical Features Associated With Restless Legs Syndrome.
|
||
| Withdrawn |
NCT03849001 -
Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS
|
N/A | |
| Completed |
NCT03076541 -
Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements.
|
N/A | |
| Recruiting |
NCT04145674 -
A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo
|
Phase 2 | |
| Completed |
NCT02532608 -
Infra-slow Oscillations During Sleep
|
N/A | |
| Completed |
NCT01528462 -
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
|